A. S. Ciampa

1.8k total citations
17 papers, 736 citations indexed

About

A. S. Ciampa is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. S. Ciampa has authored 17 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 7 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. S. Ciampa's work include Glioma Diagnosis and Treatment (13 papers), Brain Metastases and Treatment (4 papers) and Histone Deacetylase Inhibitors Research (3 papers). A. S. Ciampa is often cited by papers focused on Glioma Diagnosis and Treatment (13 papers), Brain Metastases and Treatment (4 papers) and Histone Deacetylase Inhibitors Research (3 papers). A. S. Ciampa collaborates with scholars based in United States, Switzerland and Italy. A. S. Ciampa's co-authors include Jan Drappatz, Lisa Doherty, Patrick Y. Wen, Andrew D. Norden, Debra C. LaFrankie, Santosh Kesari, E. C. Quant, Alona Muzikansky, Rameen Beroukhim and Tracy T. Batchelor and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

A. S. Ciampa

17 papers receiving 714 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. S. Ciampa United States	12	500	262	208	197	133	17	736
Yolanda Ruano Spain	13	270 0.5×	314 1.2×	147 0.7×	111 0.6×	74 0.6×	40	712
Gordon A. Watson United States	17	274 0.5×	190 0.7×	73 0.4×	357 1.8×	74 0.6×	61	944
Dolly Aguilera United States	15	293 0.6×	296 1.1×	49 0.2×	161 0.8×	154 1.2×	46	676
Arif N. Ali United States	14	219 0.4×	134 0.5×	125 0.6×	221 1.1×	29 0.2×	27	664
Jeremy McGuire United States	10	237 0.5×	320 1.2×	257 1.2×	111 0.6×	30 0.2×	20	740
Patrick D. Evers United States	8	188 0.4×	320 1.2×	278 1.3×	144 0.7×	21 0.2×	40	707
Yufang Zhu China	13	117 0.2×	162 0.6×	131 0.6×	73 0.4×	79 0.6×	41	518
Hirotomo Tanaka Japan	13	211 0.4×	184 0.7×	146 0.7×	90 0.5×	198 1.5×	35	611
Xian Zhang China	17	237 0.5×	354 1.4×	200 1.0×	97 0.5×	32 0.2×	40	843

Countries citing papers authored by A. S. Ciampa

Since Specialization

Citations

This map shows the geographic impact of A. S. Ciampa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. S. Ciampa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. S. Ciampa more than expected).

Fields of papers citing papers by A. S. Ciampa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. S. Ciampa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. S. Ciampa. The network helps show where A. S. Ciampa may publish in the future.

Co-authorship network of co-authors of A. S. Ciampa

This figure shows the co-authorship network connecting the top 25 collaborators of A. S. Ciampa. A scholar is included among the top collaborators of A. S. Ciampa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. S. Ciampa. A. S. Ciampa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Drappatz, Jan, Jeffrey J. Raizer, David Schiff, et al.. (2011). A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG).. Journal of Clinical Oncology. 29(15_suppl). 2050–2050. 6 indexed citations

Hammond, Sue, Andrew D. Norden, Jan Drappatz, et al.. (2011). Phase II study of dose-intense temozolomide in recurrent glioblastoma.. Journal of Clinical Oncology. 29(15_suppl). 2038–2038. 8 indexed citations

Norden, Andrew D., Shota Tanaka, Jan Drappatz, et al.. (2011). Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. Journal of Neuro-Oncology. 106(1). 121–125. 71 indexed citations

Drappatz, Jan, E. Q. Lee, Samantha N. Hammond, et al.. (2011). Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. Journal of Neuro-Oncology. 107(1). 133–138. 62 indexed citations

Norden, Andrew D., Jan Drappatz, Surasak Phuphanich, et al.. (2011). Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.. Journal of Clinical Oncology. 29(15_suppl). 2040–2040. 10 indexed citations

Lu‐Emerson, Christine, Andrew D. Norden, Jan Drappatz, et al.. (2010). Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. Journal of Neuro-Oncology. 104(1). 287–291. 54 indexed citations

Lu‐Emerson, Christine, Andrew D. Norden, Jan Drappatz, et al.. (2010). Retrospective study of dasatinib in recurrent high-grade glioma (HGG) patients who failed bevacizumab.. Journal of Clinical Oncology. 28(15_suppl). e12525–e12525. 1 indexed citations

Drappatz, Jan, Andrew D. Norden, Eric T. Wong, et al.. (2010). Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 78(1). 85–90. 68 indexed citations

Norden, Andrew D., Jan Drappatz, A. S. Ciampa, et al.. (2010). Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients.. Journal of Clinical Oncology. 28(15_suppl). 2043–2043. 3 indexed citations

10.

Quant, E. C., Andrew D. Norden, Jan Drappatz, et al.. (2009). Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-Oncology. 11(5). 550–555. 141 indexed citations

11.

Norden, Andrew D., Jan Drappatz, A. S. Ciampa, et al.. (2008). Colon perforation during antiangiogenic therapy for malignant glioma. Neuro-Oncology. 11(1). 92–95. 16 indexed citations

12.

Kesari, Santosh, David Schiff, John W. Henson, et al.. (2008). Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncology. 10(3). 300–308. 80 indexed citations

13.

Mariotto, Sofia, A. S. Ciampa, Elena Darra, et al.. (2008). Aqueous Extract of Arbutus unedo Inhibits STAT1 Activation in Human Breast Cancer Cell Line MDA-MB-231 and Human Fibroblasts Through SHP2 Activation. Medicinal Chemistry. 4(3). 219–228. 11 indexed citations

14.

Drappatz, Jan, Eric T. Wong, David Schiff, et al.. (2008). A Pilot Safety Study of Lenalidomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology*Biology*Physics. 73(1). 222–227. 42 indexed citations

15.

Quant, E. C., Andrew D. Norden, Jan Drappatz, et al.. (2008). Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen. Journal of Clinical Oncology. 26(15_suppl). 2008–2008. 25 indexed citations

16.

Kesari, Santosh, David Schiff, Jan Drappatz, et al.. (2008). Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults. Clinical Cancer Research. 15(1). 330–337. 112 indexed citations

17.

Nicholas, Patrice K., et al.. (2007). Distal Sensory Polyneuropathy in the Context of HIV/AIDS. Journal of the Association of Nurses in AIDS Care. 18(4). 32–40. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact